108P Pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts): Impact of blood-based biomarkers on survival outcomes

Authors :: H. Raja
L. Cove-Smith
Fiona H Blackhall
S. Hughes
Colin R Lindsay
C.J. Ackermann
Paul Taylor
Raffaele Califano
Mathew Carter
Yvonne Summers
R. Tay
A. Ortega Franco
Source :: Annals of Oncology. 31:S284
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
Blood based biomarkers
business.industry
Internal medicine
medicine
non-small cell lung cancer (NSCLC)
Hematology
Pembrolizumab
medicine.disease
business

Full Text Access

Tools